documented in 19543 and subsequently Reckless et al.4 reported the successful treatment of 3 patients with primary aortoenteric fistulae, one involving jejunum and 2 duodenum, and reviewed 128 other cases of which 81.6% involved the duodenum, 8.0% the small intestine, 5.6% the large intestine and 4.8% the stomach. Only 8 out of 18 patients with aortoduodenal fistulae treated surgically survived.
Atherosclerosis accounts for the majority of primary aortoenteric fistulae, and 2 ofour cases were of the inflammatory type. Mycotic, syphilitic and tuberculous aneurysms are less common causes, but accounted for 22 of those reviewed by Reckless et al.4 Another series of 31 cases of aortoenteric fistulae' included only 2 patients with primary lesions, both of whom died. Buckels et al.6 reviewed 546 aortic aneurysms of which only 4 presented with aortoduodenal fistulae. Three died from sepsis or renal failure but one survived for six years; he received antibiotics for the initial postoperative year.
These patients pose a challenge, not only in operative and postoperative management, but also in diagnosis. Frequently, as with our third patient, there is no history of aortic aneurysm or peptic ulcer, nor is a mass palpable. Furthermore, in a series of 7044 postmortems, peptic ulcers were found three times more often in association with abdominal aortic aneurysm than in the general population7. Blood loss may initially be intermittent and slight, allowing time for upper gastrointestinal endoscopy or radiological investigation. Of 125 patients a quarter died within six hours, but two-thirds had a history ofone day to more than one week4. In all our 3 cases the diagnosis was suspected preoperatively.
At laparotomy, blood was present in the small bowel. The stomach and first part of the duodenum were seen to be free of ulceration and the aneurysm confirmed. Control of the aorta above the fistula was not difficult after mobilizing the duodenojejunal flexure. The lower end ofthe aneurysm was dealt with in the usual fashion, after which the duodenum was separated from the aorta to disclose the fistula and the aneurysm opened. The duodenum was -closed transversely in two layers and aortic Dacron grafting completed. That part of the aortic wall involved in the fistula was excised and care taken to interpose omentum between the graft and the duodenum. Cefuroxime was given for 10 days.
In dealing with secondary aortoenteric fistulae, an infected graft is present. Either resection and further grafting with separate duodenal repair or aortic stump closure with axillofemoral bypass have been recommended for these cases. In primary fistulae the former technique should be satisfactory unless there is small bowel or colonic involvement, when the risk of sepsis is such that extra-anatomic bypass is advised, and in all patients long-term antibiotic therapy is recommended.
Graft-associated sepsis remains a fearful late complication. In our second case, who was well for two-and-a-half years following repair ofhis aortoduodenal fistula, it is possible that appendicitis rather than the original fistula was the source of his late graft infection.
The diagnosis of primary aortoenteric fistula should be considered in patients presenting with either haematemesis or melaena when an aortic aneurysm is present and bleeding peptic ulcer has been excluded. During the next 48 hours, multiple pulmonary emboli as a cause for this syncope became apparent, with the development of pyrexia, atrial fibrillation, signs of deep vein thrombosis of the right leg, right posterior pleural friction rub, small right pleural effusion on chest X-ray, a reduction in arterial Pb2 (69 mmHg) and Pco2 (27 mmHg) and a transient rise in bilirubin. A ventilation perfusion scan confirmed the diagnosis of multiple pulmonary emboli with large perfusion defects at the right base and the right mid-zone and in the left mid-zone. The ventilation scan was normal. Following anticoagulation with heparin and then warfarin, the patient remained well with no further syncope.
Discussion
Thames and colleagues' reported 3 patients who presented with syncope in whom the diagnosis of pulmonary embolism was considerably delayed due to lack of clinical suspicion of this mode of presentation. Their subsequent review showed that syncope was a common symptom (13% of 132 cases) in pulmonary embolism, and others2 found syncope to be a feature in 31% of patients with large or medium pulmonary emboli. Pulmonary embolism may masquerade as pneumonia, congestive cardiac failure, myocardial infarction, chronic obstructive airways disease, angina, pleurisy or carcinoma of the lung3. The case reported here presented with syncope but no other features to suggest pulmonary emboli, and illustrates that pulmonary emboli may also masquerade as causes of syncope such as Stokes-Adams attacks. Hepatic lipid and lipoprotein metabolism In presenting the opening paper, D N Brindley (University of Nottingham) pointed out that the regulation of fatty acid metabolism was generally well understood. Synthesis and degradation (by fioxidation) usually showed an inverse relationship, pivoting on the availability of malonyl-CoA. This intermediate in fatty acid synthesis inhibits foxidation and its production is regulated by acetyl-CoA carboxylase, an enzyme stimulated by citrate and insulin and inhibited by fatty acids and glucagon. By contrast, hepatic triglyceride synthesis is more complex as fatty acids can be derived from three sources (de novo synthesis, diet, or mobilization from adipocytes) and they may be utilized for phospholipid as well as triglyceride synthesis; its control is subject to both precursor availability and hormonal status, particularly the levels of insulin and the stress hormones. Secretion of very-low-density lipoprotein (VLDL) particles by the liver depends on the coordinated synthesis of triglyceride (60% of VLDL) and lecithin (20%), a process achieved by the fatty acid-stimulated translocation of phosphatidate phosphohydrolase and CTP-phosphocholine cytidylyltransferase from the cytosol to the endoplasmic reticulum. The central role of the liver in lipoprotein metabolism was described by A K Soutar (Royal Postgraduate Medical School, London). As well as secreting (VLDL and high-density lipoproteins, HDL) and degrading lipoprotein molecules (chylomicron remnants, low-density lipoproteins (LDL) and HDLI), the liver also appears to play a role in the transformation of triglyceride-rich VLDL to smaller, cholesteryl ester-rich LDL particles and in the interconversion of the HDL sub-classes, processes dependent on hepatic synthesis of lecithin-cholesterol acyltransferase (LCAT), hepatic lipase and, probably, lipid transfer proteins. Apoprotein B, with a molecular weight of about 513 kDA (apoB-100), is assembled into triglyceride-rich VLDL particles and retained throughout their conversion to LDL, whilst half the plasma HDL is derived from hepatic secretion of discoidal complexes of apoA-I, phospholipid and cholesterol. Both particles are modified in the circulation; VLDL acquires apoE and apoC, and nascent HDL is converted to mature spherical HDL following esterification of surface cholesterol by LCAT (a process implicated in centripetal cholesterol transport).
The LDL-receptor on the hepatocyte surface is subject to regulation and its activity is increased if hepatic cholesterol synthesis is blocked or if the enterohepatic bile acid circulation is perturbed. Chylomicron remnants appear to be cleared by a separate hepatic receptor, specific for apoE and not subject to regulation. Evidence for this apoE-receptor has included studies in LDL-receptor defective animals (patients with familial homozygous hypercholesterolaemia and the Watanabe-heritable hyperlipidaemic rabbit) which showed that clear-0141-0768/87/ 070461-04/$02.00/0 o 1987 The Royal Society of Medicine
